These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 20919963)
1. Thiopurines in Crohn's disease, is there something new? Miheller P; Lakatos PL Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1505-14. PubMed ID: 20919963 [TBL] [Abstract][Full Text] [Related]
2. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981 [TBL] [Abstract][Full Text] [Related]
3. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143 [TBL] [Abstract][Full Text] [Related]
4. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442 [TBL] [Abstract][Full Text] [Related]
5. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Seidman EG Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587 [TBL] [Abstract][Full Text] [Related]
6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Gearry RB; Barclay ML J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561 [TBL] [Abstract][Full Text] [Related]
7. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817 [TBL] [Abstract][Full Text] [Related]
8. Recent advances using immunomodulators for inflammatory bowel disease. Nielsen OH; Bjerrum JT; Herfarth H; Rogler G J Clin Pharmacol; 2013 Jun; 53(6):575-88. PubMed ID: 23408468 [TBL] [Abstract][Full Text] [Related]
9. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Yenson PR; Forrest D; Schmiegelow K; Dalal BI Am J Hematol; 2008 Jan; 83(1):80-3. PubMed ID: 17696202 [TBL] [Abstract][Full Text] [Related]
10. [When is drug therapy with azathioprine indicated in Crohn's disease?]. Rogler G; Herfarth H Dtsch Med Wochenschr; 2002 May; 127(22):1213-4. PubMed ID: 12035120 [No Abstract] [Full Text] [Related]
11. Thiopurine therapy in inflammatory bowel disease. Ha C; Dassopoulos T Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143 [TBL] [Abstract][Full Text] [Related]
12. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Sanderson J; Ansari A; Marinaki T; Duley J Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacological and pharmacogenetic study of two immunomodulators: azathioprine and 6-mercaptopurine. Strategies for preventing complications]. Wolf A; Burnat P; Garcia-Hejl C; Ceppa F Gastroenterol Clin Biol; 2009 Mar; 33(3):176-84. PubMed ID: 19243907 [TBL] [Abstract][Full Text] [Related]
14. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity]. Corominas H; Díaz C; Vázquez G; Baiget M Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415 [No Abstract] [Full Text] [Related]
16. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508 [TBL] [Abstract][Full Text] [Related]
17. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Kwan LY; Devlin SM; Mirocha JM; Papadakis KA Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898 [TBL] [Abstract][Full Text] [Related]
18. [Crohn's disease: no advantage by azathioprine and 6-mercaptopurine]. Schreiber S Dtsch Med Wochenschr; 2013 Sep; 138(38):1877. PubMed ID: 24022448 [No Abstract] [Full Text] [Related]
19. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects]. Schwab M; Herrlinger K; Schaeffeler E; Stange EF Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624 [No Abstract] [Full Text] [Related]
20. [Role of thiopurine agents in ulcerative colitis]. Chaparro M; Gisbert JP Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():30-5. PubMed ID: 25443224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]